GCP
CBAY

GSA Capital Partners’s Cymabay Therapeutics CBAY Stock Holding History

GSA Capital Partners’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17,468
Closed -$152K – 2039
2023
Q1 		$152K Sell
17,468
-48,861
-74% -$391K 0.02% 1304
2022
Q4 		$416K Sell
66,329
-32,700
-33% -$124K 0.05% 715
2022
Q3 		$347K Buy
99,029
+36,835
+59% +$132K 0.05% 830
2022
Q2 		$183K Sell
62,194
-130,050
-68% -$311K 0.03% 1094
2022
Q1 		$598K Sell
192,244
-38,014
-17% -$120K 0.08% 426
2021
Q4 		$778K Sell
230,258
-33,966
-13% -$129K 0.1% 329
2021
Q3 		$964K Buy
264,224
+133,552
+102% +$526K 0.1% 325
2021
Q2 		$570K Sell
130,672
-55,645
-30% -$247K 0.06% 547
2021
Q1 		$846K Buy
186,317
+33,520
+22% +$180K 0.14% 167
2020
Q4 		$877K Buy
+152,797
New +$1.16M 0.14% 170
2020
Q1 		– Sell
-197,290
Closed -$387K – 1669
2019
Q4 		$387K Buy
197,290
+151,187
+328% +$568K 0.05% 839
2019
Q3 		$236K Buy
46,103
+3,818
+9% +$23.1K 0.03% 1086
2019
Q2 		$303K Buy
+42,285
New +$479K 0.03% 997
2018
Q4 		– Sell
-62,500
Closed -$693K – 1827
2018
Q3 		$693K Buy
+62,500
New +$776K 0.04% 911
2018
Q1 		– Sell
-66,200
Closed -$609K – 1875
2017
Q4 		$609K Sell
66,200
-84,900
-56% -$726K 0.04% 844
2017
Q3 		$1.22M Buy
+151,100
New +$1.02M 0.08% 389

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

GSA Capital Partners's CBAY Position: Q2 2023 in Review

GSA Capital Partners sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 17,468 shares — an estimated $152K sold.

GSA Capital Partners first reported a position in CBAY in Q3 2017 and held it in 16 quarters. The position peaked at $1.22M in Q3 2017. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

  • GSA Capital Partners reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
  • GSA Capital Partners sold 17,468 Cymabay Therapeutics shares in Q2 2023, an estimated $152K.
  • GSA Capital Partners first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 16 quarters.
  • GSA Capital Partners's Cymabay Therapeutics position peaked at $1.22M in Q3 2017.
  • 151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on GSA Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.